Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Alzheimer’s Disease: Can It Improve Memory and Slow Cognitive Decline?
Transcript
- 0:00SPEAKER_00: Welcome to the Cyrona Cell Podcast.
- 0:02SPEAKER_00: When you hear the word stem cell therapy for Alzheimer's disease, you probably, you know, picture scientists in a high-tech lab growing brand new, shiny brain cells in a petri dish, right?
- 0:12SPEAKER_02: Right, yeah.
- 0:13SPEAKER_02: Like they are just gonna open up the brain and drop them in.
- 0:16SPEAKER_00: Exactly.
- 0:17SPEAKER_00: You imagine them taking those new cells and just dropping them in to replace the ones that died.
- 0:21SPEAKER_00: But uh what if I told you the most effective treatments right now aren't actually replacing a single brain cell?
- 0:27SPEAKER_02: Which is such a wild concept to grasp at first.
- 0:30SPEAKER_00: It really is.
- 0:31SPEAKER_00: Yeah.
- 0:31SPEAKER_00: They're actually acting more like a team of microscopic paramedics putting out massive biochemical fires.
- 0:37SPEAKER_00: So today our mission is to cut through the noise, skip the science fiction, and provide a breedily clear, science-backed explanation of what regenerative medicine is actually doing for cognitive decline.
- 0:48SPEAKER_02: Yeah, and we are gonna ground this in some very specific real-world source material today.
- 0:54SPEAKER_00: All right.
- 0:54SPEAKER_00: Today's sources are clinical guides and facility overviews from Cyrona Cell, which is a doctor-led regenerative medicine center based in Kuolumpur, Malaysia.
- 1:04SPEAKER_00: We're gonna briefly introduce how a structured facility like theirs operates in this space.
- 1:09SPEAKER_02: It is a profound shift in how we think about the brain.
- 1:13SPEAKER_02: And I want to warmly welcome you, the listener, to this deep dive, because whether you are someone who is just, you know, insanely curious about the cutting edge of human biology, which is a lot of you I know.
- 1:25SPEAKER_02: Oh, for sure.
- 1:26SPEAKER_02: Or, and this is very common, you are searching for better, clearer ways to help a mom, a dad, or a loved one manage memory loss.
- 1:34SPEAKER_02: This conversation is designed as a tool for you.
- 1:37SPEAKER_00: Yeah.
- 1:37SPEAKER_00: Absolutely.
- 1:37SPEAKER_02: Our goal is to give you the biological clarity you need to navigate these options without uh without being overswomed by the hype.
- 1:44SPEAKER_00: Okay, let's unpack this.
- 1:45SPEAKER_00: Because before we can even touch on the concept of repairing the brain, we need a hyper-clear picture of what is actually breaking down inside it.
- 1:51SPEAKER_00: Let's look at the battlefield.
- 1:52SPEAKER_02: Aaron Powell The Battlefield is a great way to put it.
- 1:54SPEAKER_00: Right, because Alzheimer's is a progressive condition.
- 1:56SPEAKER_00: It compounds over time.
- 1:57SPEAKER_02: Yeah.
- 1:58SPEAKER_00: But the specific villain here, the biological culprit driving the memory loss and behavior changes, is the buildup of something called tau protein.
- 2:06SPEAKER_02: Yeah, the tau protein misfolding is really the critical piece of the pathology to understand.
- 2:10SPEAKER_02: To visualize this, you have to look inside a healthy nerve cell or a neuron.
- 2:15SPEAKER_02: Okay.
- 2:15SPEAKER_02: Neurons have these long, beautiful transport systems.
- 2:19SPEAKER_02: Think of them like microscopic train tracks that carry nutrients and essential supplies from one end of the cell to the other.
- 2:25SPEAKER_00: Right.
- 2:25SPEAKER_00: So they are the supply lines.
- 2:27SPEAKER_02: Exactly.
- 2:28SPEAKER_02: And in a healthy brain, tau protein is the glue.
- 2:32SPEAKER_02: It literally acts like the railroad ties holding those tracks perfectly straight and stable.
- 2:36SPEAKER_00: Aaron Powell But in an Alzheimer's brain, those railroad ties warp.
- 2:40SPEAKER_02: Right.
- 2:40SPEAKER_00: They detach from the tracks and clump together.
- 2:42SPEAKER_02: Aaron Ross Powell Precisely.
- 2:43SPEAKER_02: They form these uh these abnormal, twisted structures known as neurofibulary tangles inside the cells.
- 2:49SPEAKER_00: Neurofibrillary tangles, that just sounds destructive.
- 2:52SPEAKER_02: It is.
- 2:52SPEAKER_02: When the tau protein stops doing its job and starts clumping, the train tracks fall apart.
- 2:58SPEAKER_02: The cell can no longer transport nutrients, it essentially starves.
- 3:02SPEAKER_00: Wow.
- 3:03SPEAKER_00: So it's quite literally a cellular supply chain crisis.
- 3:07SPEAKER_00: If I picture the brain as a massive, bustling city, the communication networks, you know, the roads and highways connecting all the different neighborhoods are being completely blocked by this toxic tau debris.
- 3:21SPEAKER_02: That is exactly what is happening, yeah.
- 3:23SPEAKER_00: And because the roads are blocked, the supplies can't get through in those specific neighborhoods, the actual brain tissue just shut down.
- 3:30SPEAKER_00: And the reality of that shutdown is severe.
- 3:33SPEAKER_02: It is devastating.
- 3:34SPEAKER_02: Over time, this communication breakdown causes the brain to literally shrink.
- 3:38SPEAKER_00: Like actually lose physical size.
- 3:40SPEAKER_02: Yes.
- 3:40SPEAKER_02: The clinical term is brain atrophy.
- 3:43SPEAKER_02: It's not just a functional decline, you know, it is a physical, measurable loss of brain mass.
- 3:48SPEAKER_00: That is terrifying.
- 3:49SPEAKER_02: If you look at an MRI of advanced Alzheimer's, the brain tissue has visibly pulled away from the skull.
- 3:54SPEAKER_02: The physical structure of the central nervous system is degrading.
- 3:57SPEAKER_02: Right.
- 3:58SPEAKER_00: The hardware itself is breaking down.
- 3:59SPEAKER_02: Which is exactly why daily tasks, recognizing faces or forming words, become so profoundly difficult.
- 4:07SPEAKER_02: The hardware is vanishing.
- 4:09SPEAKER_00: I hear what you're saying about the hardware vanishing, but this raises a huge red flag for me.
- 4:14SPEAKER_00: If the tau protein is already suffocating the cells and causing the brain to shrink, aren't we just putting a band-aid on a bullet wound with these new therapies?
- 4:24SPEAKER_02: I see where you're going with this.
- 4:26SPEAKER_00: Like, are these new treatments trying to clear the debris or are they trying to rebuild the neighborhoods?
- 4:31SPEAKER_02: If we connect this to the bigger picture, the scientific goal is actually a bit of both.
- 4:35SPEAKER_02: Regenerative medicine in this context isn't just throwing new cells at a dying organ.
- 4:39SPEAKER_00: Right.
- 4:39SPEAKER_00: It's not just dropping them in.
- 4:41SPEAKER_02: No, not at all.
- 4:42SPEAKER_02: It is looking at how to fundamentally alter the environment of the brain.
- 4:46SPEAKER_02: The first priority is to protect the surviving central nervous system from further damage.
- 4:50SPEAKER_00: So stopping the toxic debris from taking out more roads.
- 4:53SPEAKER_02: Exactly.
- 4:54SPEAKER_02: And the second priority is supporting the native repair of the cellular infrastructure that has been injured but isn't entirely dead yet.
- 5:01SPEAKER_00: Okay, that distinction changes how I look at this entirely.
- 5:04SPEAKER_00: We know the brain's natural defenses are completely overwhelmed.
- 5:08SPEAKER_00: So how do scientists actually provide reinforcements?
- 5:12SPEAKER_00: Let's get into the stem cell arsenal.
- 5:14SPEAKER_02: The arsenal is expanding rapidly, but there are definitely tiers to it.
- 5:17SPEAKER_00: Yeah, the sources mention researchers generally focus on three main types of cells, usually testing them extensively in mouse models before they ever get near a human trial.
- 5:26SPEAKER_02: That's standard protocol, yes.
- 5:27SPEAKER_02: Safety first.
- 5:29SPEAKER_00: I want to start with the one that sounds the most futuristic.
- 5:35SPEAKER_02: Oh, they are an absolute marvel of modern science.
- 5:38SPEAKER_02: Induced pluripotent stem cells are essentially adult cells, like a regular skin cell that scientists have genetically reprogrammed to revert back to an embryonic-like state.
- 5:48SPEAKER_00: Here's where it gets really interesting.
- 5:50SPEAKER_00: You're saying we can take a skin cell, hit a biological rewind button, and program it to become a brand new brain cell.
- 5:57SPEAKER_02: In a laboratory setting, yes.
- 5:58SPEAKER_00: That sounds like pure science fiction.
- 6:00SPEAKER_00: Can we really just program a cell to become a brand new brain cell, or is the reality more complicated?
- 6:05SPEAKER_02: The short answer is no, not today.
- 6:08SPEAKER_02: The reality is vastly more complicated.
- 6:10SPEAKER_02: Pluripotency means the cell has the power to become any tissue in the body.
- 6:15SPEAKER_00: Any tissue at all?
- 6:16SPEAKER_02: Any tissue.
- 6:17SPEAKER_02: And while that is a staggering potential for future regenerative treatments, I mean literally the holy grail of tissue replacement, it carries massive risks right now.
- 6:27SPEAKER_00: Because it's unpredictable.
- 6:28SPEAKER_02: Exactly.
- 6:29SPEAKER_02: If a cell can become anything, it might grow unpredictably.
- 6:32SPEAKER_02: It could form the wrong type of tissue or even a tumor.
- 6:35SPEAKER_00: Oh wow.
- 6:36SPEAKER_00: Yeah, that is a massive risk.
- 6:37SPEAKER_02: So long-term safety and outcome data for IPSCs are still being intensely studied in labs.
- 6:43SPEAKER_02: They are the future, but they are not the present clinical standard.
- 6:46SPEAKER_00: Aaron Powell Okay, so if IPSCs are still in a lab, what about neural stem cells or NSCs?
- 6:52SPEAKER_00: Aaron Ross Powell, Jr.
- 6:52SPEAKER_02: Neural stem cells are highly specialized.
- 6:55SPEAKER_02: Unlike IPSCs that can become bone, muscle, or brain, NSCs are already committed to becoming nerve tissue.
- 7:01SPEAKER_01: So they already have their career path picked out.
- 7:03SPEAKER_02: Exactly.
- 7:03SPEAKER_02: They are being researched for their ability to integrate directly into the brain circuitry.
- 7:07SPEAKER_02: But again, while they are closer to application, they're largely still under strict clinical research.
- 7:13SPEAKER_00: Which brings us to the actual workhorses of current clinical care.
- 7:18SPEAKER_00: Misenchymal stem cells or MSCs?
- 7:21SPEAKER_02: Yes, the MSCs.
- 7:22SPEAKER_00: These are the ones actually being utilized widely right now.
- 7:24SPEAKER_00: And this is the part that completely flipped my understanding.
- 7:27SPEAKER_00: As we said at the top of the show, MSCs don't necessarily work by turning into new brain cells to replace the dead ones.
- 7:33SPEAKER_00: Right.
- 7:34SPEAKER_00: You call them cellular paramedics earlier.
- 7:36SPEAKER_00: Break down that mechanism for me.
- 7:38SPEAKER_00: How does a stem cell act like a paramedic?
- 7:40SPEAKER_02: It comes down to something called the peracrine effect.
- 7:43SPEAKER_02: When MSCs are introduced into the body, they have this unique homing ability.
- 7:48SPEAKER_00: Homing ability, like a heat-seeking missile.
- 7:50SPEAKER_02: Kind of, yeah.
- 7:51SPEAKER_02: They naturally seek out areas of severe inflammation, which in an Alzheimer's brain is everywhere.
- 7:57SPEAKER_00: Because the whole city is on fire.
- 7:58SPEAKER_02: Precisely.
- 7:59SPEAKER_02: But instead of trying to become a neuron, they act as cellular managers.
- 8:03SPEAKER_02: They arrive and start releasing a highly specific cocktail of cytokines, exosomes, and growth factors.
- 8:10SPEAKER_00: Okay, cytokines, what are those?
- 8:11SPEAKER_02: Think of cytokines as biochemical text messages.
- 8:15SPEAKER_00: Okay.
- 8:15SPEAKER_02: The Alzheimer's brain is in a state of hyperinflammation.
- 8:18SPEAKER_02: The brain's own immune cells are panicking, acting aggressively, and often inadvertently damaging healthy tissue in their attempt to clear out the tau protein.
- 8:28SPEAKER_01: Aaron Powell So the immune system is basically doing more harm than good at that point.
- 8:32SPEAKER_02: Exactly.
- 8:32SPEAKER_02: So the MSCs arrive on the scene and send out these cytokine text messages to the local immune cells, essentially saying, stand down, turn off the hyperinflammation.
- 8:42SPEAKER_00: Wow.
- 8:42SPEAKER_00: So they are actively hacking the brain's immune response.
- 8:46SPEAKER_02: They really are.
- 8:46SPEAKER_02: By lowering that rampant neuroinflammation, they change the entire microenvironment.
- 8:52SPEAKER_02: They put out the biochemical fires.
- 8:53SPEAKER_00: Which buys the surviving cells' time.
- 8:55SPEAKER_02: Yes.
- 8:56SPEAKER_02: This protects the surviving neurons from dying off, helps reduce the toxic buildup of debris, and creates a stable environment that encourages the brain's own native repair mechanisms to finally kick in.
- 9:07SPEAKER_00: That is incredible.
- 9:08SPEAKER_02: They aren't laying bricks, you know?
- 9:10SPEAKER_02: They are directing traffic, calming the immune system, and handing blueprints to the body's natural construction crews.
- 9:16SPEAKER_00: That is a massive aha moment for me.
- 9:19SPEAKER_00: It's not about replacing the brain, it's about rescuing the environment.
- 9:22SPEAKER_00: But uh that biological reality naturally forces a reality check about what this actually means for a patient seeking help today.
- 9:30SPEAKER_02: Yes, it absolutely does.
- 9:32SPEAKER_00: If you're listening to this right now and you're watching a parent's memory slip away, you are probably desperately wondering, is it too late?
- 9:39SPEAKER_00: Will this give me my dad back?
- 9:40SPEAKER_00: We have to talk about the timelines and limitations here.
- 9:43SPEAKER_02: We must.
- 9:44SPEAKER_02: Because in regenerative medicine, managing expectations with biological facts is a moral imperative.
- 9:50SPEAKER_00: Right.
- 9:51SPEAKER_00: The potential benefits of NSC therapies are remarkable, improving memory, stabilizing cognitive function, protecting the central nervous system, and radically reducing brain inflammation.
- 10:01SPEAKER_02: All very real benefits.
- 10:02SPEAKER_00: But the sources state incredibly clearly that this is not a complete cure.
- 10:07SPEAKER_00: It is not a magic eraser for Alzheimer's.
- 10:09SPEAKER_00: The results vary wildly between patients.
- 10:12SPEAKER_02: And that variability is deeply tied to the physical state of the brain at the time of treatment.
- 10:16SPEAKER_00: Right, which brings up the ideal candidate.
- 10:19SPEAKER_00: The data shows that patients in the early stages of Alzheimer's see the most profound benefits.
- 10:26SPEAKER_00: Conversely, advanced cases see very limited improvement.
- 10:30SPEAKER_00: So, what does this all mean?
- 10:33SPEAKER_00: Why does a therapy so powerful suddenly hit a wall in late stage patients?
- 10:37SPEAKER_02: What's fascinating here is how the sheer physical reality of the brain dictates the timeline.
- 10:42SPEAKER_02: Let's go back to your city analogy.
- 10:44SPEAKER_00: Okay, the blocked roads.
- 10:45SPEAKER_02: Right.
- 10:45SPEAKER_02: If a few roads are blocked by tau debris and a couple of neighborhoods are cut off and struggling, those MSC paramedics can rush in.
- 10:53SPEAKER_02: They can clear the smoke, lower the inflammation, and help the local cells repair the damage.
- 10:58SPEAKER_02: The network can be safe.
- 10:59SPEAKER_00: Because the infrastructure is still mostly there.
- 11:01SPEAKER_02: Exactly.
- 11:01SPEAKER_02: But in late stage Alzheimer's My brain is shrunk.
- 11:04SPEAKER_02: Right.
- 11:04SPEAKER_02: In late stage Alzheimer's, as we discussed with brain atrophy, the entire neighborhood has been leveled.
- 11:08SPEAKER_02: The buildings are physically gone.
- 11:10SPEAKER_00: I see.
- 11:11SPEAKER_02: Dropping in a team of cellular managers won't magically rebuild a skyscraper out of thin air if the infrastructure no longer exists.
- 11:18SPEAKER_02: The neurons are dead, and the brain mass has shrunk.
- 11:22SPEAKER_02: MSCs protect and support what is there.
- 11:25SPEAKER_02: They cannot resurrect tissue that has been completely lost.
- 11:28SPEAKER_00: So the biological clock is ticking from day one.
- 11:31SPEAKER_02: Timing is everything.
- 11:32SPEAKER_02: The critical importance of early intervention just cannot be overstated.
- 11:36SPEAKER_00: Which makes sense based on the biology.
- 11:38SPEAKER_02: It does.
- 11:38SPEAKER_02: If a family is exploring this, they must view regenerative medicine as a powerful adjunct to a broader care plan.
- 11:45SPEAKER_02: It's a way to slow disease progression, reduce inflammation, and improve the quality of life.
- 11:50SPEAKER_02: It is a strategic tool, not a one-and-done cure.
- 11:52SPEAKER_00: That transitions perfectly into the clinical standard.
- 11:55SPEAKER_00: If early intervention is key, how do you actually get this done safely?
- 11:59SPEAKER_00: We transition from the theoretical biology into the real-world application by looking at Sorona cell, which is a structured doctor-led center operating right now in Kuala Lumpur, Malaysia.
- 12:09SPEAKER_02: Looking closely at how a specific facility operates provides a fantastic blueprint for what ethical modern stem cells care should actually look like.
- 12:17SPEAKER_00: Yeah, and Sarona cell serves local patients, but they also highlight a massive influx of international patients traveling from places like Australia and the Middle East for this specific care.
- 12:27SPEAKER_02: Which speaks to the global demand for structured facilities.
- 12:30SPEAKER_00: Definitely.
- 12:31SPEAKER_00: By the way, the name Sorona comes from a Celtic goddess of health and protection.
- 12:35SPEAKER_00: They use it to symbolize a commitment to science-led care over the uh quick fix promises that unfortunately plague a lot of the internet.
- 12:44SPEAKER_02: Oh, the medical tourism space for stem cells can be a minefield of bad actors making impossible claims.
- 12:50SPEAKER_02: You have to look at the strict science a clinic is utilizing.
- 12:53SPEAKER_00: Let's look at their science then.
- 12:54SPEAKER_00: They explicitly state they exclusively use ethically sourced early passage WJMSCs.
- 13:01SPEAKER_02: Yes, WJMSCs.
- 13:03SPEAKER_00: Wait, pause for a second.
- 13:04SPEAKER_00: Wharton's jelly.
- 13:05SPEAKER_00: That sounds like a bizarre breakfast spread, not a medical breakthrough.
- 13:09SPEAKER_00: What exactly is that and why does early passage matter?
- 13:12SPEAKER_02: I know.
- 13:12SPEAKER_02: It is an odd name, I admit.
- 13:13SPEAKER_02: Wharton's jelly is actually the gelatinous connective tissue found inside a human umbilical cord.
- 13:18SPEAKER_00: Oh, wow.
- 13:19SPEAKER_00: Okay.
- 13:19SPEAKER_02: Yeah, so when a healthy baby is born at full term, the umbilical cord is usually just thrown away as medical waste.
- 13:26SPEAKER_02: But with strict donor consent, scientists can harvest the incredibly potent mesenchymal stem cells living inside that jelly.
- 13:33SPEAKER_00: Aaron Powell Oh, so that's why they are ethically sourced.
- 13:36SPEAKER_00: No embryos involved whatsoever.
- 13:38SPEAKER_02: Correct.
- 13:39SPEAKER_02: Cirona cell explicitly states they do not use embryonic stem cells or those experimental pluripotent cells we discussed earlier.
- 13:46SPEAKER_01: Aaron Ross Powell Right, the unpredictable ones.
- 13:48SPEAKER_02: Exactly.
- 13:49SPEAKER_02: They stick to adult stem cell lines from umbilical cords because they have a proven safety profile, they don't form tumors, and they have massive anti-inflammatory properties.
- 13:58SPEAKER_00: Okay, that covers the Wharton's jelly part and the early passage part.
- 14:02SPEAKER_02: When you grow cells in a lab, every time they multiply and divide, that is a passage.
- 14:07SPEAKER_02: If you copy a cell too many times, you know, passage after passage, it gets tired, it loses its potency, and it can even mutate.
- 14:14SPEAKER_00: Like a photocopy of a photocopy.
- 14:16SPEAKER_02: That is the perfect analogy, yes.
- 14:18SPEAKER_02: Early passage means the clinic is using young, vibrant cells that are only a few generations removed from the original source.
- 14:26SPEAKER_02: They're at their absolute peak paramedic capability.
- 14:29SPEAKER_00: Aaron Powell That makes total sense.
- 14:31SPEAKER_00: And their laboratory safety standards match that exact rigor.
- 14:35SPEAKER_00: The sources mention they utilize BSL2 laboratory standards, CGMP, which stands for Current Good Manufacturing Practice, and ISO 9001 Certified Quality Systems.
- 14:46SPEAKER_02: Which is a very impressive list.
- 14:47SPEAKER_00: Now I know that's an alphabet stoop of acronyms, but what it means in plain English is that the environment is locked down against contamination.
- 14:55SPEAKER_02: Those acronyms are the difference between world-class medicine and a dangerous backroom operation.
- 15:00SPEAKER_02: One detail that really stands out is their focus on identity and viability checks.
- 15:05SPEAKER_00: Meaning they check if the cells are actually alive.
- 15:07SPEAKER_02: Exactly.
- 15:08SPEAKER_02: Before a patient ever receives an infusion, the lab team verifies the exact cellular identity in the vial.
- 15:14SPEAKER_02: And critically, they count how many of those cells are alive and active.
- 15:18SPEAKER_00: Because dead cells aren't going to do anything.
- 15:20SPEAKER_02: If a clinic infuses dead cells, you get absolutely zero of those crucial cytokine text messages.
- 15:28SPEAKER_02: The therapy is useless.
- 15:29SPEAKER_00: And the delivery method itself is minimally invasive.
- 15:33SPEAKER_00: We are talking about 5e infusions or targeted injections.
- 15:37SPEAKER_00: There is no open brain surgery happening in their standard protocols.
- 15:41SPEAKER_02: Right.
- 15:41SPEAKER_02: It's very manageable for the patient.
- 15:44SPEAKER_00: But honestly, beyond the BSL2 labs and the cell counting, the thing that struck me the most about Cyroticell setup is their physician philosophy.
- 15:52SPEAKER_02: The clinical depth, yes.
- 15:53SPEAKER_02: Yeah.
- 15:54SPEAKER_00: They have teams spanning neurology, internal medicine, and rehab.
- 15:57SPEAKER_02: Yeah.
- 15:58SPEAKER_00: And they share a commitment to clinical depth and highly transparent advice.
- 16:02SPEAKER_00: In fact, they explicitly state that their doctors will tell a patient when stem cell therapy is not appropriate for them.
- 16:08SPEAKER_02: That right there is the hallmark of ethical medicine, a willingness to say no.
- 16:12SPEAKER_00: It really is.
- 16:12SPEAKER_02: Yeah.
- 16:13SPEAKER_00: It makes me view this structured approach, coordinating with a patient's doctors back home, tracking side effects, and rigorously managing long-term outcomes as the only way this industry builds real trust.
- 16:22SPEAKER_01: Absolutely.
- 16:23SPEAKER_00: It ensures the therapy is integrated into the patient's entire life, not just sold as a miracle injection in a vacuum.
- 16:29SPEAKER_02: And that brings us full circle to you, the listener.
- 16:32SPEAKER_02: Navigating an Alzheimer's diagnosis for your family is profoundly isolating.
- 16:37SPEAKER_02: It feels like you are drowning in complex medical jargon and terrifying statistics.
- 16:41SPEAKER_00: It really does.
- 16:42SPEAKER_02: But understanding the biological mechanisms, knowing how tau protein blocks the roads, and how MSEs act as paramedics to put out the inflammatory fires that knowledge empowers you.
- 16:53SPEAKER_00: Knowledge is power.
- 16:54SPEAKER_02: It is.
- 16:55SPEAKER_02: Knowing what a safe, ethical, and highly regulated clinic looks like means you don't have to fall victim to hype.
- 17:01SPEAKER_02: It allows you to make calm, informed, strategic decisions about your family's care plan.
- 17:06SPEAKER_00: So to summarize our deep dive today, Alzheimer's is a physical breakdown of the brain's communication networks, leading to real tissue loss.
- 17:13SPEAKER_00: But modern stem cell therapies, specifically mesenchymal stem cells, offer a scientifically grounded way to halt that neuroinflammation, rescue the surviving networks, and protect the brain.
- 17:24SPEAKER_02: Beautifully summarized.
- 17:25SPEAKER_00: And when administered early and safely at a facility adhering to the highest global standards, it is a formidable tool in the fight against cognitive decline.
- 17:35SPEAKER_02: It truly is.
- 17:36SPEAKER_00: As we wrap up today, I want to leave you with a thought to mull over something that builds on everything we've uncovered.
- 17:41SPEAKER_00: If treatments using mesenchymal stem cells are proving so effective at reducing inflammation and managing immune responses, what if the ultimate future of aging isn't about finding a single cure for diseases like Alzheimer's, but rather learning how to proactively tune up our body's own regenerative systems long before the damage ever begins?